AstraZeneca Rating Increased to Neutral at Bank of America Corp. (AZN)
AstraZeneca (LON:AZN) was upgraded by analysts at Bank of America Corp. from an “underperform” rating to a “neutral” rating in a research report issued to clients and investors on Monday, ARN reports. The firm currently has a GBX 3,400 ($55.01) target price on the stock, up from their previous target price of GBX 3,200 ($51.77). Bank of America Corp.’s price objective would suggest a potential upside of 3.28% from the company’s current price.
A number of other firms have also recently commented on AZN. Analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Friday, October 25th. They now have a GBX 3,220 ($52.10) price target on the stock. Separately, analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Thursday, October 24th. They now have a GBX 2,863.67 ($46.33) price target on the stock. Finally, analysts at Nordea Equity Research reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Wednesday, October 23rd. They now have a GBX 3,877.70 ($62.74) price target on the stock. Twelve investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and a consensus price target of GBX 3,097.49 ($50.11).
AstraZeneca (LON:AZN) traded down 1.14% during mid-day trading on Monday, hitting GBX 3291.9998. The stock had a trading volume of 2,245,327 shares. AstraZeneca has a 52-week low of GBX 442.867 and a 52-week high of GBX 3544.50. The stock has a 50-day moving average of GBX 3210.14 and a 200-day moving average of GBX 3257.37. The company’s market cap is £41.216 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.